1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. Financials
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
Delayed Nasdaq  -  05/20 04:00:01 pm EDT
199.65 USD   +3.40%
05/12Roche believes cancer drug setback not a fatal blow to growth prospects
RE
05/10Biogen Says Eisai Submits Biologics License Application for Lecanemab for Alzheimer's Disease to FDA
MT
05/09Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 53 54337 67935 24229 239--
Enterprise Value (EV)1 51 73341 72337 82030 05925 96922 199
P/E ratio 9,44x9,87x23,1x14,2x12,3x13,2x
Yield ------
Capitalization / Revenue 3,72x2,80x3,21x2,97x3,11x3,11x
EV / Revenue 3,60x3,10x3,44x3,06x2,76x2,36x
EV / EBITDA 6,41x5,56x9,13x8,40x7,25x5,99x
Price to Book 3,87x3,70x3,26x2,30x1,99x1,75x
Nbr of stocks (in thousands) 180 442153 882146 893146 452--
Reference price (USD) 297245240200200200
Announcement Date 01/30/202002/03/202102/03/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 14 37813 44510 9829 8349 3969 391
EBITDA1 8 0707 5044 1443 5773 5843 706
Operating profit (EBIT)1 7 3906 8373 6562 9622 9742 953
Operating Margin 51,4%50,9%33,3%30,1%31,7%31,4%
Pre-Tax Profit (EBT)1 7 1265 0481 7452 3443 1072 834
Net income1 5 8894 0011 5561 9962 2772 057
Net margin 41,0%29,8%14,2%20,3%24,2%21,9%
EPS2 31,424,810,414,116,215,1
Dividend per Share2 ------
Announcement Date 01/30/202002/03/202102/03/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 2 7792 7342 5322 4862 4382 401
EBITDA1 1 018781844843901884
Operating profit (EBIT)1 885646709784762692
Operating Margin 31,9%23,6%28,0%31,5%31,3%28,8%
Pre-Tax Profit (EBT)1 291405347837617578
Net income1 329368304734509467
Net margin 11,8%13,5%12,0%29,5%20,9%19,5%
EPS2 2,222,502,065,543,603,24
Dividend per Share ------
Announcement Date 10/20/202102/03/202205/03/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 -4 0442 578819--
Net Cash position1 1 810---3 2707 040
Leverage (Debt / EBITDA) -0,22x0,54x0,62x0,23x-0,91x-1,90x
Free Cash Flow1 6 5643 8053 3822 5042 8332 844
ROE (Net Profit / Equities) 47,7%45,2%26,6%19,1%17,2%15,9%
Shareholders' equity1 12 3428 8415 85810 47613 26412 952
ROA (Net Profit / Asset) 24,0%15,4%11,9%8,74%8,58%8,40%
Assets1 24 58325 92713 12422 85526 54524 483
Book Value Per Share2 76,666,273,586,9101114
Cash Flow per Share2 38,026,224,319,219,620,5
Capex1 515425258277280288
Capex / Sales 3,58%3,16%2,35%2,82%2,98%3,07%
Announcement Date 01/30/202002/03/202102/03/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Key data
Capitalization (USD) 29 239 144 395
Net sales (USD) 10 981 700 000
Number of employees 9 610
Sales / Employee (USD) 1 142 737
Free-Float 85,4%
Free-Float capitalization (USD) 24 976 328 827
Avg. Exchange 20 sessions (USD) 266 490 105
Average Daily Capital Traded 0,91%
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA